This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
CDKN1B · Western blot design guide
CDKN1B Western Blot Planning Guide
Plan a CDKN1B Western blot around the catalog-observed 22.1 kDa band, image-backed PB9070 evidence, HPA controls, and verified protocol records.
Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
CDKN1B Western Blot Experimental Design Guide
Expected bands, documented protocol parameters, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | 22.1 kDa | |
| Observed band | Not reported — verify product WB image | |
| Gel | 12-15% | |
| Positive control | Cervix | |
| Negative control | Soft tissue |
Important caveats
Reasons your observed band may differ from the expected size.
| ⓘ | Calculated mass | 22.1 kDa |
| ⓘ | Localization | Nucleus / Cytoplasm |
| ⓘ | Processing / PTM | Record-dependent |
| ⓘ | Reactivity | Human |
Section 1
Real Curated CDKN1B Western Blot Protocols
Start with the molecular-weight rule, then compare verified publication-derived conditions.
| Sample / lysate | Bone marrow |
| Gel % | 12-15% |
| Load | 20-30 µg total protein per lane |
| Transfer | Semi-dry, short transfer |
| Membrane | 0.45 µm PVDF |
| Blocking | 5% non-fat milk or 5% BSA in TBST |
| Primary | PB9070 at datasheet starting dilution |
| Primary incubation | Overnight at 4 °C with gentle agitation |
| Secondary | Species-matched HRP conjugate at validated dilution |
| Wash | 3 × 5 min in TBST |
| Detection | Chemiluminescent substrate |
| Exposure | Bracket exposures to avoid saturation |
Section 2
What Is the Expected CDKN1B Western Blot Band Size?
Use the product-observed 22.1 kDa band as the primary planning value and retain the UniProt calculated mass as context.
| 22.1 kDa | Matches the authoritative product WB observation. |
| 22.1 kDa calculated | Use as UniProt context, not as a replacement observed band. |
| Unexpected additional signal | Do not assign identity without orthogonal positive/negative controls. |
💡Expected CDKN1B appearancePlan around 22.1 kDa and keep the calculated mass as supporting context.
| Catalog-observed band | 22.1 kDa; use this as the primary experimental expectation. |
| Calculated mass | 22.1 kDa from UniProt P46527; retain as context. |
| Gel selection | 12-15%; shared with the recommended protocol and poster. |
| Specificity check | Compare the lead HPA positive and negative controls with PB9070. |
| Situation | Likely cause | Next action |
|---|---|---|
| 22.1 kDa | Matches the authoritative product WB observation. | Confirm with orthogonal controls and the linked product record. |
| Additional band | May reflect processing, modification, or non-specific signal. | Run a dilution series and compare positive/negative controls. |
| Weak signal | Target abundance or transfer may be limiting. | Verify transfer, increase positive-control abundance, and bracket exposure. |
Experiment evidence
Western blot images showing CDKN1B band
PB9070 · CDKN1B
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for CDKN1B Western blot
🧪Use Cervix as the first positive-control candidate and Soft tissue as the HPA Not detected negative candidate.
Positive control: Cervix (High)
Negative control: Soft tissue (Not detected)
HPA protein score determines control status; other expression data is supporting context only.
HPA tissue expression evidence for CDKN1B
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Cervix | Reported tissue cells | High | Protein (HPA) | HPA → |
| Cerebellum | Reported tissue cells | High | Protein (HPA) | HPA → |
| Caudate | Reported tissue cells | High | Protein (HPA) | HPA → |
| Hippocampus | Reported tissue cells | High | Protein (HPA) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Soft tissue | Reported tissue cells | Not detected | Protein (HPA) | HPA → |
Section 3
Advanced CDKN1B Western Blot Tips
Deeper troubleshooting and optimisation questions for CDKN1B, answered from its protein features.
Which band should guide the blot?
Use 22.1 kDa, the observation attached to the authoritative PB9070 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 22.1 kDa expectation.
Which positive control should I start with?
Start with Cervix, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use Soft tissue as an orthogonal HPA Not detected candidate.
Which gel should I use?
Use 12-15% consistently across the quick facts, protocol table, and poster.
What transfer method to use for CDKN1B Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should PB9070 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
No verified publication protocol was supplied; use only the deterministic recommended protocol.
Boster reagents
CDKN1B Western Blot Reagents
Human-reactive CDKN1B Western blot reagents with authoritative product imagery.
Real WB data
Anti-p27 KIP 1/CDKN1B Antibody Picoband®
Cat # PB9070
Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.
Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.
References
- UniProt P46527
- Human Protein Atlas — CDKN1B
- PB9070 product record
- PMC6754294 — Notch and the pre-TCR coordinate thymocyte proliferation by induction of the SCF subunits Fbxl1 and Fbxl12 (Nature immunology, 2019)
- PMC3708111 — Deficiency of the cyclin-dependent kinase inhibitor, CDKN1B, results in overgrowth and neurodevelopmental delay (Human mutation, 2013)
- PMC10063447 — PRMT6-CDC20 facilitates glioblastoma progression via the degradation of CDKN1B (Oncogene, 2023)
